June 19, 2026; By Benjamin Kosubevsky
In Palm Beach, Palm Beach Gardens, and Wellington—communities where residents invest significantly in their cardiovascular health through diet, exercise, and preventive cardiology—an emerging body of research is raising questions about a factor that most standard cardiac evaluations do not assess: cumulative heavy metal burden.
Peer-reviewed research has identified associations between chronic heavy metal exposure and cardiovascular disease risk. Lead, cadmium, mercury, and arsenic have each been studied for their potential effects on endothelial function, oxidative stress, and inflammatory pathways in the vascular system. A comprehensive review in EXS documented the multi-system toxicity of these metals, including their cardiovascular implications (Tchounwou et al., EXS, 2012).
A separate review examined the mechanisms by which specific metals may contribute to atherosclerosis, hypertension, and other cardiovascular pathology, noting that the relationship between chronic low-level exposure and long-term cardiovascular outcomes is an area of active scientific investigation (Jaishankar et al., Interdisciplinary Toxicology, 2014).
The most significant clinical evidence connecting chelation therapy to cardiovascular outcomes comes from the Trial to Assess Chelation Therapy (TACT). This NIH-funded, randomized, double-blind, placebo-controlled trial enrolled 1,708 patients aged 50 and older with a history of myocardial infarction. Patients receiving 40 IV EDTA chelation treatments showed a statistically significant reduction in a composite endpoint of death, reinfarction, stroke, coronary revascularization, and hospitalization for angina, compared to placebo (Lamas et al., JAMA, 2013). The effect was especially pronounced in diabetic participants, where the chelation group experienced a 41% relative reduction in the primary endpoint. A follow-up study, TACT2, was subsequently funded to further investigate these findings in diabetic patients specifically.
For health-conscious residents of Palm Beach, Palm Beach Gardens, and Wellington who are already engaged in proactive cardiovascular care, heavy metal testing represents a relatively simple addition to their existing health surveillance. If elevated levels are found, chelation therapy may be worth discussing with a physician who understands both the TACT evidence and the limitations of the current data.
At The Longevity Center FL in West Palm Beach, Dr. Kosubevsky offers both heavy metal testing and IV EDTA chelation therapy for patients whose laboratory findings and clinical profile support its use.
IV chelation therapy is not FDA-approved as a treatment for cardiovascular disease. The TACT trial results are promising but represent a single study, and the medical community has not reached consensus on routine chelation for cardiovascular risk reduction. This blog is for educational purposes only.
Give Us a Call +1 (561) 210-4033
Schedule a consultation at The Longevity Center FL in West Palm Beach. [Schedule an Appointment]
The information in this blog post is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Individual results vary. This content is not intended to be a substitute for professional medical advice. Always consult a qualified healthcare professional regarding any medical condition, symptom, medication, or treatment decision. Peer-reviewed research cited reflects population-level or study-level findings and does not predict individual outcomes. The Longevity Center FL does not claim to diagnose, treat, cure, or prevent any disease through the services discussed.
Cardiovascular Health and Heavy Metal Burden: An Emerging Conversation in Palm Beach County
IV Chelation Therapy vs. Oral Chelation: How to Evaluate Your Options
Heavy Metal Exposure in Coastal Florida: What Jupiter and Treasure Coast Residents Should Know
Chronic Fatigue, Brain Fog, and Low Energy: Could Blood Oxygenation Help?
EBOO vs. Traditional Ozone Therapy: Understanding the Key Differences